Lisinopril
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
ACE Inhibitors | Lisinopril | 2.5-10mg PO Q24-48H | Administer Post HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
405 | 88-100 | 30 | 40-50 | 0 | 1-3.8 | 34.4-47.7 | 51 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00722
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010; 23(3):290-7.
- Kelly J, Doyle G, Carmody M, Glover D, Cooper W. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. British journal of clinical pharmacology. 1988; 26(6):781-6.
- Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007; 27(5):522-9.